Purpose The aim of this study was to evaluate the cost-effectiveness of apixaban compared
with to warfarin, current standard of care, for stroke prevention in patients with nonvalvular …

Objective: To investigate the risk of bleeding events and stroke/systemic embolism (SE)
among Japanese patients with nonvalvular atrial fibrillation (NVAF), focusing on the initial …

Objectives Many of the cost-effectiveness analyses of apixaban against warfarin focused on
Western populations but Asian evidence remains less clear. The present study aims to …

Background The perceived risk of serious bleeding is an obstacle to the use of oral
anticoagulation in East Asia. The efficacy and safety of apixaban in East Asian patients with …

In the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation
(ARISTOTLE) trial, apixaban is comparable to a vitamin K antagonist (VKA) in reducing …

Background Apixaban was shown to be superior to adjusted-dose warfarin in preventing
stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional …

Introduction Economic evaluations are becoming increasingly important due to limitations in
economic resources, the expense of many new treatments, the need to allocate health …

Aims Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke
prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients …

Abstract Background and Objective Evidence indicates that vitamin K antagonists (VKAs)
and oral anticoagulant therapy are under-utilised for stroke prevention in patients with non …

Background Strokes attributed to atrial fibrillation (AF) represent a major cause of adult
disability and a great burden to society and healthcare systems. Objectives Our objective …